Literature DB >> 6440908

Evaluation of focus reduction neutralization test with peroxidase-antiperoxidase staining technique for hemorrhagic fever with renal syndrome virus.

O Tanishita, Y Takahashi, Y Okuno, K Yamanishi, M Takahashi.   

Abstract

Titers of hemorrhagic fever with renal syndrome virus were estimated by counting foci stained with peroxidase-antiperoxidase or by using immunofluorescence methods. Foci stained with PAP were clearer and easier to count. The peroxidase-antiperoxidase method showed a linear relationship between virus concentration and the number of foci. A focus-reduction neutralizing antibody test was performed with immune rat sera and sera from patients. Again, the peroxidase-antiperoxidase method proved to be more convenient and reliable than the immunofluorescence method. Antigenic differences between Hantaan virus, 76-118 and hemorrhagic fever with renal syndrome virus B-1 were clearly demonstrated by the neutralizing antibody test.

Entities:  

Mesh:

Year:  1984        PMID: 6440908      PMCID: PMC271555          DOI: 10.1128/jcm.20.6.1213-1215.1984

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  14 in total

1.  OCCURRENCE OF EPIDEMIC HEMORRHAGIC FEVER IN OSAKA CITY: FIRST CASES FOUND IN JAPAN WITH CHARACTERISTIC FEATURE OF MARKED PROTEINURIA.

Authors:  M TAMURA
Journal:  Biken J       Date:  1964-10

2.  Isolation of the etiologic agent of Korean Hemorrhagic fever.

Authors:  H W Lee; P W Lee; K M Johnson
Journal:  J Infect Dis       Date:  1978-03       Impact factor: 5.226

3.  Isolation of hemorrhagic fever with renal syndrome (HFRS) virus from a tumor specimen in a rat.

Authors:  K Yamanishi; J R Dantas; M Takahashi; T Yamanouchi; K Domae; J Kawamata; T Kurata
Journal:  Biken J       Date:  1983-12

4.  Isolation of virus causing hemorrhagic fever with renal syndrome (HFRS) through a cell culture system.

Authors:  T Kitamura; C Morita; T Komatsu; K Sugiyama; J Arikawa; S Shiga; H Takeda; Y Akao; K Imaizumi; A Oya; N Hashimoto; S Urasawa
Journal:  Jpn J Med Sci Biol       Date:  1983-02

5.  Clinical features of HFRS in Scandinavia as compared with East Asia.

Authors:  J Lähdevirta
Journal:  Scand J Infect Dis Suppl       Date:  1982

Review 6.  Korean hemorrhagic fever.

Authors:  H W Lee
Journal:  Prog Med Virol       Date:  1982

7.  New hemorrhagic fever with renal syndrome-related virus in rodents in the United States.

Authors:  P W Lee; H L Amyx; D C Gajdusek; R T Yanagihara; D Goldgaber; C J Gibbs
Journal:  Lancet       Date:  1982-12-18       Impact factor: 79.321

8.  Morphological identification of the agent of Korean haemorrhagic fever (Hantaan virus)as a member of the Bunyaviridae.

Authors:  J B McCormick; D R Sasso; E L Palmer; M P Kiley
Journal:  Lancet       Date:  1982-04-03       Impact factor: 79.321

9.  Virus hemorrhagic fevers. Special reference to hemorrhagic fever with renal syndrome (epidemic hemorrhagic fever).

Authors:  D C GAJDUSEK
Journal:  J Pediatr       Date:  1962-06       Impact factor: 4.406

10.  Etiologic studies of epidemic hemorrhagic fever (hemorrhagic fever with renal syndrome).

Authors:  G Song; C S Hang; X Z Qui; D S Ni; H X Liao; G Z Gao; Y L Du; J K Xu; Y S Wu; J N Zhao; B X Kong; Z S Wang; Z Q Zhang; H K Shen; N Zhou
Journal:  J Infect Dis       Date:  1983-04       Impact factor: 5.226

View more
  18 in total

1.  Rapid focus reduction neutralization test of influenza A and B viruses in microtiter system.

Authors:  Y Okuno; K Tanaka; K Baba; A Maeda; N Kunita; S Ueda
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

2.  Role of maternal antibody in protection from hemorrhagic fever with renal syndrome virus infection in rats.

Authors:  X K Zhang; I Takashima; N Hashimoto
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

3.  Expression of interferon inducible genes following Hantaan virus infection as a mechanism of resistance in A549 cells.

Authors:  Jae-Hwan Nam; Kyung-A Hwang; Cheong-Hee Yu; Tae-Hoon Kang; Jae-Young Shin; Woo-Young Choi; In-Beom Kim; Young-Ran Joo; Hae-Wol Cho; Keun-Yong Park
Journal:  Virus Genes       Date:  2003-01       Impact factor: 2.332

4.  Rapid focus reduction neutralization test of Japanese encephalitis virus in microtiter system. Brief report.

Authors:  Y Okuno; T Fukunaga; M Tadano; Y Okamoto; T Ohnishi; M Takagi
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

5.  Characteristics of passive immunity against hantavirus infection in rats.

Authors:  X K Zhang; I Takashima; N Hashimoto
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

6.  Serotypic classification of hantaviruses by indirect immunofluorescent antibody and plaque reduction neutralization tests.

Authors:  P W Lee; C J Gibbs; D C Gajdusek; R Yanagihara
Journal:  J Clin Microbiol       Date:  1985-12       Impact factor: 5.948

7.  Antigenic characterization of Hantaan and Seoul virus nucleocapsid proteins expressed by recombinant baculovirus: application of a truncated protein, lacking an antigenic region common to the two viruses, as a serotyping antigen.

Authors:  M Morii; K Yoshimatsu; J Arikawa; G Zhou; H Kariwa; I Takashima
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

8.  Protective role of antigenic sites on the envelope protein of Hantaan virus defined by monoclonal antibodies.

Authors:  J Arikawa; J S Yao; K Yoshimatsu; I Takashima; N Hashimoto
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

9.  Antibody-dependent enhancement of hantavirus infection in macrophage cell lines.

Authors:  J S Yao; H Kariwa; I Takashima; K Yoshimatsu; J Arikawa; N Hashimoto
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

10.  Puumala hantavirus viremia diagnosed by real-time reverse transcriptase PCR using samples from patients with hemorrhagic fever and renal syndrome.

Authors:  Magnus Evander; Irene Eriksson; Lisa Pettersson; Per Juto; Clas Ahlm; Gert E Olsson; Göran Bucht; Annika Allard
Journal:  J Clin Microbiol       Date:  2007-05-30       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.